New vaccine aims to shield kids from Post-Transplant virus
NCT ID NCT03354728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a vaccine called CMV-MVA Triplex in 80 children who have had a stem cell transplant and are at risk for CMV infection. The goal is to find the best dose and see if it safely prevents CMV reactivation. Participants receive the vaccine and are monitored for side effects and effectiveness over one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CMV-MVA Triplex Vaccine
- What this could lead to
- If it works, this vaccine could help prevent serious CMV infections in children after stem cell transplants, reducing complications and the need for antiviral drugs.
- What could go wrong
- This is an early phase 1/2 trial with only 80 participants, so results may not apply to everyone. The vaccine may cause side effects or not work as expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New vaccine aims to shield transplant patients from deadly virus
- Donor vaccine may shield transplant patients from dangerous virus
- Saliva swabs could replace needles for virus monitoring in ovarian cancer patients
- Donor T-Cells take on stubborn CMV in transplant patients
- Engineered immune cells take on viruses in cancer patients